A Look At ImmunityBio (IBRX) Valuation As ANKTIVA Rollout Drives Rapid Product Revenue Growth

Simply Wall St.05-03

ImmunityBio (IBRX) is back on investor radars after reporting a 168% year over year increase in quarterly product revenue, driven by ANKTIVA’s commercial rollout across the US, Europe, Macau, and ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2632160374?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","is_english":true,"pubTime":"2026-05-03 09:52","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2632160374","market":"us","top_or_hot":-1,"title":"A Look At ImmunityBio (IBRX) Valuation As ANKTIVA Rollout Drives Rapid Product Revenue Growth","media":"Simply Wall St.","content":"<div>\n<p>ImmunityBio (IBRX) is back on investor radars after reporting a 168% year over year increase in quarterly product revenue, driven by ANKTIVA’s commercial rollout across the US, Europe, Macau, and ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ibrx/immunitybio/news/a-look-at-immunitybio-ibrx-valuation-as-anktiva-rollout-driv\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>A Look At ImmunityBio (IBRX) Valuation As ANKTIVA Rollout Drives Rapid Product Revenue Growth</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nA Look At ImmunityBio (IBRX) Valuation As ANKTIVA Rollout Drives Rapid Product Revenue Growth\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-05-03 09:52 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ibrx/immunitybio/news/a-look-at-immunitybio-ibrx-valuation-as-anktiva-rollout-driv><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>ImmunityBio (IBRX) is back on investor radars after reporting a 168% year over year increase in quarterly product revenue, driven by ANKTIVA’s commercial rollout across the US, Europe, Macau, and ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ibrx/immunitybio/news/a-look-at-immunitybio-ibrx-valuation-as-anktiva-rollout-driv\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IBRX","symbol_name":"ImmunityBio, Inc.","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ibrx/immunitybio/news/a-look-at-immunitybio-ibrx-valuation-as-anktiva-rollout-driv","article_id":"2632160374","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ibrx/immunitybio/news/a-look-at-immunitybio-ibrx-valuation-as-anktiva-rollout-driv","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2632160374","pubTimestamp":1777773131,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"ImmunityBio (IBRX) is back on investor radars after reporting a 168% year over year increase in quarterly product revenue, driven by ANKTIVA’s commercial rollout across the US, Europe, Macau, and Saudi Arabia.\nSee our latest analysis for ImmunityBio.\nDespite the strong ANKTIVA rollout, ImmunityBio’s recent share price return has cooled, with a 7 day share price return of a 4.4% decline and a 30 day share price return of a 2.6% decline. However, the year to date share price return of 252% and...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"IBRX":"ImmunityBio, Inc."},"translate_title":"ANKTIVA的推出推动产品收入快速增长，看看ImmunityBio(IBRX)的估值","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IBRX":1.5},"content_text":"ImmunityBio (IBRX) is back on investor radars after reporting a 168% year over year increase in quarterly product revenue, driven by ANKTIVA’s commercial rollout across the US, Europe, Macau, and Saudi Arabia. See our latest analysis for ImmunityBio. Despite the strong ANKTIVA rollout, ImmunityBio’s recent share price return has cooled, with a 7 day share price return of a 4.4% decline and a 30 day share price return of a 2.6% decline. However, the year to date share price return of 252% and 1 year total shareholder return of 180% still point to powerful momentum built over a longer horizon. If ANKTIVA’s growth story has caught your attention, it could be a good moment to see what else is emerging across healthcare AI, starting with 33 healthcare AI stocks With ImmunityBio now generating US$113.3 million in revenue but still reporting a net loss of US$351.4 million, and with the share price trading below the average analyst target, are you looking at a genuine opportunity, or at a market that is already pricing in future growth? AdvertisementMost Popular Narrative: 47.3% Undervalued ImmunityBio's most followed narrative puts fair value at $13.50, well above the last close of $7.11, which hinges heavily on aggressive growth and margin assumptions.  The rapid global expansion of ANKTIVA into 33 countries, including the U.S., EU, U.K., and Saudi Arabia, together with commercial partners like Accord and regional distributors, sets up a much larger treated patient base over time, which is directly tied to future product revenue growth.  Read the complete narrative. Curious what justifies that gap between price and fair value? The narrative leans on steep revenue ramps, a sharp earnings swing and a premium future earnings multiple. Result: Fair Value of $13.50 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, this hinges on ANKTIVA expanding beyond bladder cancer and regulators accepting ImmunityBio’s trial designs, outcomes that could still differ from what analysts expect. Find out about the key risks to this ImmunityBio narrative. Next Steps With sentiment clearly split between opportunity and concern, this is a good moment to look at the numbers yourself and move quickly while forming your own view with 2 key rewards and 4 important warning signs Ready to find your next idea? Do not stop with a single stock when there are hundreds of other potential opportunities waiting for a closer look. Let the data work for you.  Spot potential bargains quickly by checking companies that screen as high quality and possibly mispriced through the 51 high quality undervalued stocks. Prioritise resilience by reviewing companies that pass the 70 resilient stocks with low risk scores with stronger risk profiles than the broader market. Hunt for earlier stage opportunities by scanning the 24 elite penny stocks with strong financials that also show stronger underlying financials.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2632160374","isCrawlerRequest":true}